



CE Marked Material
QCRPARVB19QC1 - Anti-Parvovirus B19 Quality Control Serum
Sample 1
NIBSC code: QCRPARVB19QC1
Instructions for use
(Version 4.0, Dated 10/04/2024)

This material is a self certified IVD and complies with the requirements of the "EU in vitro diagnostic medical device directive 98/79/EC"

1. INTENDED USE

This product is CE marked for use as an IVD within the UK, EU member states and EEA countries. In all other territories this product can be used for research purposes only.

Anti-Parvovirus B19 QC1 is intended for use in the internal laboratory quality control of immunoassays that detect IgG antibodies to Parvovirus B19. The anti-Parvovirus B19 QC1 should be included in each run as part of a continuing quality control programme to monitor the performance of the assay. Data obtained with the anti-Parvovirus B19 QC1 can be used to construct quality control charts that can be visually monitored each time the assay is run, to check for consistency of performance of the assay. Examples of how these charts are constructed and used have been described elsewhere¹. Anti-Parvovirus B19 QC1 is NOT INTENDED TO BE USED TO COMPARE THE SENSITIVITY OF PARTICULAR ASSAYS.

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The anti-Parvovirus B19 QC1 has been prepared from an anti-Parvovirus B19 donation, repeatedly reactive in commercial EIA kits and commercial line blot assays. The reactive donation used to prepare anti-Parvovirus B19 QC1 was non-reactive for anti-HIV, HBsAg and anti-HCV using commercial EIA kits. The reactive donations were then diluted in a pool of defibrinated human plasma samples non-reactive for anti-Parvovirus B19. These samples were also non-reactive for HBsAg, anti-HCV and anti-HIV using commercial EIA kits. Bronidox[®]P was added to a concentration of 0.05%(w/v) as a preservative. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

Table 1 gives a summary of the results obtained for anti-Parvovirus B19 QC1 15/B678. These results are intended only as a guide to the approximate levels of reactivity to be expected, and may not be exactly reproduced in other laboratories. In each case, at a minimum, three samples of anti-Parvovirus B19 QC1 were tested on two separate occasions. The results are expressed as the ratio of mean optical density or other measurement of the anti-Parvovirus B19 response of the QC1 sample, to the kit manufacturer's calculated cut-off.

4. CONTENTS

Country of origin of biological material: United Kingdom.
Ready-to-use reagent
REF QCRPARVB19QC1 1x7mL Blood Tubes

Defibrinated Plasma 4mL
Bronidox[®] 0.05% (w/v)

5. STORAGE

Reagents are to be kept at 2-8°C upon receipt
o Reagents may be stored at 2-8°C until use by date. Do not use after expiry date
o Reagents should be divided into measured sub-aliquots of one use and stored below -20°C to avoid freeze/thaw cycles. Do not use after expiry date
o When thawed for use, store at 2-8°C. Once thawed, use within one month and do not refreeze. Do not use after expiry date.

6. DIRECTIONS FOR OPENING

Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

7. USE OF MATERIAL

1. Use of this reagent is to be restricted to trained laboratory staff only
2. Use suitable (latex/nitrile) gloves and eye/skin protection. Mix well before use.
3. Include reagent as a normal sample in routine work list
4. Allow reagent to reach room temperature before use
5. Plot reagent result on a QC chart to monitor performance

8. STABILITY (Add or amend as necessary)

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.
Stability studies are carried out to ensure stability of this product.

9. REFERENCES

1. Levey, S. and Jennings, E.R. (1950). The use of control charts in clinical laboratories. *Am.J.Clin.Pathol.* 20, 1059-1066

10. ACKNOWLEDGEMENTS

EC REP Advena Ltd. Tower Business Centre, 2nd Floor, Swatar, BKR 4013, Malta

11. FURTHER INFORMATION

Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
<http://www.who.int/biologicals/en/>
JCTLM Higher order reference materials:
<http://www.bipm.org/en/committees/jc/jctlm/>
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
<http://www.nibsc.org/products/ordering.aspx>
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org



Attached: No

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET (Add or amend as necessary)

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties	
Physical appearance: Liquid	Corrosive: No
Stable: Yes	Oxidising: No
Hygroscopic: No	Irritant: No
Flammable: No	Handling: See caution, Section 2
Other (specify):	
Toxicological properties	
Effects of inhalation:	Not established, avoid inhalation
Effects of ingestion:	Not established, avoid ingestion
Effects of skin absorption:	Not established, avoid contact with skin
Suggested First Aid	
Inhalation:	Seek medical advice
Ingestion:	Seek medical advice
Contact with eyes:	Wash with copious amounts of water. Seek medical advice
Contact with skin:	Wash thoroughly with water.
Action on Spillage and Method of Disposal	
Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.	

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom * Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
Net weight: 10 g
Toxicity Statement: Toxicity not assessed
Veterinary certificate or other statement if applicable.





1: Results obtained for **Anti-Parvovirus B19 QC1** (Lot Number **15/B678**) using the following EIA kits.

EIA KIT	Method Options	Test to Cut-off Ratio	
		Mean	SD (n-1)
Novagnost Parvovirus B19 IgG Manufacturer: Siemens Catalogue number: PARG0370DB Lot number: PARG-129	Standard Protocol	1.8	0.3
Biotrin Parvovirus B19 (EIA) Manufacturer: Diasorin Catalogue Number: V519IG Lot Number: 75KT063	Standard Protocol	1.6	0.2
Parvovirus B19 IgG Manufacturer: IBL International Catalogue Number: RE57281 Lot number: PARG-134-2	Standard Protocol	21.1	4.0
Liason Biotrin Parvovirus B19 IgG Manufacturer: Diasorin Catalogue Number: 317070 Lot Number: 127022	Automated Protocol	Index 2.1	0.5